Take a fresh look at your lifestyle.

Serbia to become second European country to start production of Sputnik V Covid-19 vaccine, after Russia itself — RT Russia & Former Soviet Union

The production of Sputnik V, the world’s first registered vaccine against Covid-19, has started in Serbia, the Russian developers of the Jab have announced. Italy, India and Iran are expected to follow in the coming months.

“Production of the Sputnik V vaccine started successfully in Serbia,” said Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), on Tuesday, confirming that it was “the first European country to start manufacturing the Russian vaccine “- outside of Russia itself, that is.

The RDIF, which financed the development of Sputnik V at Moscow’s Gamaleya Institute, signed a contract with the Belgrade Torlak Institute in mid-March to manufacture the vaccine in Serbia. Belgrade has been using Sputnik V since the beginning of January to vaccinate its citizens – as well as the residents of neighboring countries.

Italy has also signed a contract with the RFID but is expected to start production in the next few months. Production in Iran is expected “in the near future,” Dmitriev told reporters on Tuesday.

Also on rt.com
Sputnik V approved in India as New Delhi opens the door to Russian-made Covid-19 vaccine to more than a billion people – reported

New Delhi this week issued emergency clearance to use the vaccine developed in Russia. Three Indian manufacturers – Virchow Biotech, Stelis Biopharma and Gland Pharma – signed contracts in March to produce around 750 million cans of Sputnik V, which are due to start at the end of this year. Dmitriev told reporters Tuesday that India is projected to produce 50 million cans a month by the summer.

Sputnik V was the world’s first registered vaccine against the disease caused by the novel coronavirus and has so far been approved for use in 60 countries and territories around the world with a total population of over 3 billion people.

The vaccine developed in Russia has an efficacy of 91.6% according to data from Phase III studies published by the prestigious medical journal Lancet. It relies on well-studied adenoviral vectors to perform the immunization and there have been no reports of serious side effects with its use.

Also on rt.com
According to the developer of the pioneering Russian vaccine Sputnik V Covid-19, there are no cases of blood clots that have occurred during the trials and use of Jab

Do you like this story? Share it with a friend!

Comments are closed.